Navigation Links
KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
Date:11/1/2013

d constipation (OIC).

Mickle continued, "The next clinical milestone for KP201 will be the completion of oral and intranasal abuse liability studies in the first quarter of 2014.  These studies will be important indicators of KP201's unique abuse-deterrent capabilities, which we believe are unlike any prescription opioid on the market or in development."

About KemPharm

KemPharm is abiopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the third quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, KP606, its oxycodone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at www.kempharm.com

For KemPharm, Inc:   

Media / Investor Contacts:

Christal Mickle

319-665-2575

info@kempharm.com

Jason Rando / Joshua Drumm, Ph.D.

Tiberend Strategic Advisors, Inc.

212.827.0020


SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
2. KemPharms KP201 Featured at the International Conference on Opioids
3. Micropharma completes development of first microbiome clinical lab test using digital PCR technology
4. Syneron Medical Completes and Summarizes the Multi-site Clinical Study Agreed Upon with FDA for the UltraShape Contour I
5. AIS (American Internet Services) Completes Audit for Title 21 CFR Part 11 Compliance
6. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
7. VIVEX BIOMEDICAL Successfully Completes $7.6 Million Round of Financing
8. Boston Scientific Completes $1.05 Billion Senior Notes Offering
9. SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
10. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
11. Oligomerix, Inc. Completes Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... are not donor candidates for bone marrow transplantation. The ... elderly prone to life-threatening infection and other maladies, and ... a reason why. , "We have found the cellular ... maintain blood production over time in an old organism, ... for rejuvenation therapies," said Emmanuelle Passegu, PhD, a professor ...
(Date:7/31/2014)... organs and even the entire body to visualize long-range ... has been a long-time dream of biologists. A study ... the journal Cell has now made that ... organs, bodies, and human tissue biopsies transparent, while keeping ... pave the way for a better understanding of brain-body ...
(Date:7/31/2014)... -- Chemists at Indiana University Bloomington have described ... fashion, a development with potential value for the ... transistors and photovoltaic cells. , Their paper, "Anion-Induced ... Solids and 2D Self-Assembled Crystals," has been published ... of the Royal Society of Chemistry. It is ...
(Date:7/31/2014)... New York , July 31, 2014 ... by Transparency Market Research "Quantum Dots Market - Global ... - 2023," the market was valued at USD 88.5 ... 8,246.8 million by 2023, growing at a CAGR of ... full Quantum Dots Market Report at  http://www.transparencymarketresearch.com/quantum-dots.html ...
Breaking Biology Technology:Key to aging immune system is discovered 2See-through organs and bodies will accelerate biomedical discoveries 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4
... One of the nation,s leading independent research ... assets align to support the critical mission of protecting ... bioenergy solutions. , , Officials ... are expanding MRI,s existing operations by establishing a wholly ...
... Ga., March 31 ArunA Biomedical, Inc., a leader ... that it has been awarded a Department of Defense ... stem cell technology. (Logo: ... human embryonic stem cell derived cellular model for use ...
... today announced that it named Dr. Christopher Ahlberg, a ... to its Board of Directors. Dr. Ahlberg most ... of Tibco,s Spotfire division, dating back to 2007. Prior ... of Spotfire, Inc., a provider of enterprise analytics software ...
Cached Biology Technology:Midwest Research Institute Expands in Kansas to Support Regional Economic Development in Animal Health, Biosecurity, and Bioenergy Sectors 2Midwest Research Institute Expands in Kansas to Support Regional Economic Development in Animal Health, Biosecurity, and Bioenergy Sectors 3Midwest Research Institute Expands in Kansas to Support Regional Economic Development in Animal Health, Biosecurity, and Bioenergy Sectors 4ArunA Biomedical Awarded Department of Defense Contract to Further Develop Environmental Biosensor for National Security 2Fina Technologies Names Spotfire Founder Christopher Ahlberg to Board of Directors 2
(Date:7/31/2014)... GAINESVILLE, Fla. --- By tracing nearly 3,000 genes ... moths, University of Florida scientists have created an ... to use large-scale, next-generation DNA sequencing. , ... more closely related to small moths than to ... how butterflies evolved. The study also found that ...
(Date:7/31/2014)... pairs have identified a gene mutation that may allow the ... sleep per night. The genetic variant also appears to ... Results show that a participant with p.Tyr362His a variant ... duration of only five hours, which was more than one ... six hours and five minutes per night. The twin ...
(Date:7/31/2014)... have completed a 20-year study that looks at ... different times of the year. It finds that ... frame has no measurable negative consequences for the ... , The study was conducted by Gene Towne, ... fire chief, and Joseph Craine, research assistant professor, ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Study of twins discovers gene mutation linked to short sleep duration 2Study finds benefits to burning Flint Hills prairie in fall and winter 2Study finds benefits to burning Flint Hills prairie in fall and winter 3
... (March 29, 2011)A medical device developed by retired U.S. ... paradigm for the detection, diagnosis and monitoring of stroke, ... of Interventional Radiology,s 36th Annual Scientific Meeting in Chicago, ... detected, identified and located using a simple headset and ...
... but as genetic testing becomes more common, access to ... never faced before. It is particularly important that we ... is being collected to improve the diagnosis and treatment ... Hospitals and Clinics to begin laying the foundation for ...
... University has detected tiny amounts of Iodine 131 from Japan ... Gerald Matisoff, professor of geology, said the presence ... estimated the level of radiation is about one-tenth that of ... have come from any radioactive waste processing facility," Matisoff said. ...
Cached Biology News:New device uses submarine technology to diagnose stroke quickly 2New device uses submarine technology to diagnose stroke quickly 3
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... Rabbit polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide ... the C-terminus of Human MSY2/YBOX2. ... proprietary) (Peptide available ...
Biology Products: